Skip to main content
OpenTrials

Clinical trial condition

Refractory Acute Myeloid Leukemia

Explore clinical trials studying Refractory Acute Myeloid Leukemia. Study availability and eligibility vary by location and protocol.

103 public trials 43 recruiting studies
Refine in advanced search Browse all conditions

Refractory Acute Myeloid Leukemia trial results

Recruiting

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

NCT06834282

Conditions
AML, Acute Myeloid Leukemia, Hematologic Diseases, +7 more
Locations
  • University of California, Davis Comprehensive Cancer Center Sacramento, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Sarah Cannon Research Insitute Nashville, Tennessee, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Recruiting

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

NCT07582172

Conditions
Acute Myeloid Leukemia With Complex Karyotype, Bone Marrow Diseases, Hematologic Diseases, +17 more
Locations
  • City of Hope Medical Center Duarte, California, United States
View Trial Details
Recruiting

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

NCT07012044

Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy, Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Riley Hospital for Children Indianapolis, Indiana, United States
  • C S Mott Children's Hospital Ann Arbor, Michigan, United States
  • University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
View Trial Details
Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

NCT03471260

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Hematologic Diseases, +13 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Oregon Health and Science University Portland, Oregon, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details

Related conditions